As patients with BRAF V600E, NTRK, and RET mutations now have targeted therapy for metastatic thyroid cancer, further larger cohort prospective studies on molecular profiling could elucidate differences in thyroid cancer in Filipinos compared to other race/ethnic groups and to also see if they could explain that possible increased prevalence of features such as larger tumor sizes, lymph node involvement, and multifocality may be tied to increased incidence and mortality risks. The gene discussed is BRAF; the disease is thyroid gland carcinoma.